Epoch Investment Partners Inc. Increases Stake in United Therapeutics Co. (NASDAQ:UTHR)

Epoch Investment Partners Inc. raised its stake in United Therapeutics Co. (NASDAQ:UTHR) by 6.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 226,655 shares of the biotechnology company’s stock after purchasing an additional 13,157 shares during the period. Epoch Investment Partners Inc. owned 0.51% of United Therapeutics worth $72,201,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. ClariVest Asset Management LLC grew its stake in United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares during the last quarter. V Square Quantitative Management LLC purchased a new stake in shares of United Therapeutics during the second quarter worth about $30,000. Rise Advisors LLC purchased a new stake in shares of United Therapeutics during the first quarter worth about $32,000. Innealta Capital LLC acquired a new stake in shares of United Therapeutics during the second quarter worth about $33,000. Finally, Benjamin F. Edwards & Company Inc. lifted its holdings in shares of United Therapeutics by 63.6% during the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 117 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of research reports. TD Cowen lifted their target price on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. LADENBURG THALM/SH SH downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. Oppenheimer lifted their target price on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a report on Wednesday, August 28th. UBS Group lifted their target price on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $400.00 target price on shares of United Therapeutics in a report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $350.36.

Insiders Place Their Bets

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $312.48, for a total transaction of $1,124,928.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $40,622.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $312.48, for a total value of $1,124,928.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $40,622.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James Edgemond sold 7,785 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the completion of the sale, the chief financial officer now directly owns 2,615 shares in the company, valued at $947,597.55. The disclosure for this sale can be found here. Insiders have sold 110,922 shares of company stock valued at $36,541,398 over the last ninety days. Company insiders own 12.50% of the company’s stock.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $353.00 on Friday. The company’s 50-day moving average price is $339.19 and its 200-day moving average price is $291.68. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The company has a market cap of $15.66 billion, a P/E ratio of 16.69, a P/E/G ratio of 1.25 and a beta of 0.57. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $366.08.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The business had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. During the same period in the prior year, the business posted $5.24 earnings per share. The business’s quarterly revenue was up 19.8% on a year-over-year basis. On average, sell-side analysts forecast that United Therapeutics Co. will post 24.86 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.